Navigation Links
Nektar Therapeutics Reports Third Quarter 2009 Financial Results
Date:11/4/2009

SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2009.

Net loss for the quarter ended September 30, 2009 improved to $31.0 million or $0.33 per share, as compared to a net loss of $37.0 million or $0.40 per share in the third quarter of 2008.

Nektar continued to make improvements to its operating efficiencies as compared to a year ago. Total operating costs and expenses were down 30% to $39.1 million in the third quarter of 2009 as compared to $56.0 million in the third quarter of 2008. For the first nine months of 2009, total operating costs and expenses were down 29% to $122.6 million as compared to $171.6 million in the first nine months of 2008.

"We are extremely pleased with our success in the third quarter," said Howard W. Robin, President and Chief Executive Officer of Nektar. "We signed a landmark collaboration with AstraZeneca for NKTR-118 and NKTR-119 that highlights the compelling value we are creating in our clinical pipeline. We are also making great progress with NKTR-102, with enrollment in our Phase 2 ovarian cancer study completed ahead of schedule. Our clinical results continue to validate the potential of Nektar's proprietary advanced polymer conjugate technology in creating important new therapeutics."

Research and development expense was $23.5 million in the third quarter of 2009 as compared to $38.3 million for the same quarter in 2008. For the first nine months of 2009, research and development expense was $71.5 million as compared to $109.1 million in the same period in 2008. Included in the $71.5 million of overall research and development expenses in the first nine months of 2009 is approximately $40.0 million of investment in Nektar preclinical and clin
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... have shelled out for crude 3-D glasses, polarized ... experience. These basic devices, used to trick the ... soon be rendered obsolete with the introduction of ... researchers. , TAU doctoral students Yuval Yifat, Michal ... holography based on nanoantennas that could be used ...
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
(Date:1/15/2014)... Vernon Hills, IL (PRWEB) January 15, 2014 ... Cole-Parmer to find hard-working items for the lab, from ... designated as Guaranteed-in-Stock (GIS)—ready to ship when you order. ... Masterflex® Peristaltic Pumps , from the L/S® model ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
Breaking Biology Technology:Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... SHANGHAI, Sep. 4 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: ... Chinese firm,specializing in the manufacture, research, development, marketing ... Company,s,management team will attend the Susquehanna International Group ... The SIG 3rd Annual ...
... , AURORA, Ontario, Sept. 4 Helix BioPharma ... has accepted subscriptions for the purchase, by way of private placement, ... gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private ... unit consists of one common share and one common share purchase ...
... Kendle (Nasdaq: KNDL ), a leading, global full-service ... the upcoming Robert Baird 2009 Health Care Conference on Sept. ... New York City. , , (Logo: ... Kendle,s formal presentation will be given by Senior Vice President ...
Cached Biology Technology:China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit 2Helix BioPharma Announces $13.5 Million Private Placement 2Kendle to Present at Robert Baird 2009 Health Care Conference 2
(Date:7/10/2014)... even improve the state of fisheries resources in ... Mediterranean has deteriorated over the past 20 years. ... reported in the Cell Press journal Current ... stringent monitoring of Mediterranean fishing activities, better enforcement ... Mediterranean waters. , Their data show that the ...
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
(Date:7/10/2014)... company housed at NJIT,s business incubator, received a $1.4 ... surgeons will use to staunch bleeding during brain surgery. ... site, and the natural bio-polymer solutions in the gel ... 30 seconds. , The gel can shorten an ... into less time for the patient,s skull to be ...
Breaking Biology News(10 mins):Mediterranean fish stocks show steady decline 2Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... , This release is also available in Chinese ... it the anti-sunscreen. That,s more or less the description of ... light-catching substances that could be added to photovoltaic materials in ... electricity. Research reported in the journal ...
... 2010) Autism Speaks, Chief Science Officer Geraldine ... environmental risk factors for autism spectrum disorders as ... Works, Subcommittee on Children,s Health convened a special ... autism spectrum disorders (ASD) and related neurodevelopmental disorders. ...
... for two competitive grants to better understand and manage outbreaks ... fisheries in Puget Sound. The grants cover the first year ... the next three years. NEW FORECAST ... goal of one project is to develop a forecasting ability ...
Cached Biology News:Selenium makes more efficient solar cells 2Autism Speaks on US Senate hearing on potential environmental health factors in autism 2Autism Speaks on US Senate hearing on potential environmental health factors in autism 3New research to improve management of harmful algal blooms in Puget Sound 2
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
... The versatile Promega Flipper® Racks are ... of your small tubes. These polypropylene racks ... choice for freezer storage. They may also ... Each rack is two-sided; one side accommodates ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
...
Biology Products: